Development of the sodium-glucose co-transporter 2 inhibitor dapagliflozin for the treatment of patients with type 2 diabetes mellitus (Q37960123)

25 August 2017

Development of the sodium-glucose co-transporter 2 inhibitor dapagliflozin for the treatment of patients with type 2 diabetes mellitus (English)

1 reference

25 August 2017

0 references

0 references

1

John E Gerich

1 reference

25 August 2017

Arnaud Bastien

2

1 reference

PubMed ID

22111852

25 August 2017

language of work or name

English

0 references

publication date

1 November 2011

1 reference

Expert Review of Clinical Pharmacology

25 August 2017

1 reference

25 August 2017

4

1 reference

25 August 2017

6

1 reference

25 August 2017

669-683

1 reference

Standards of medical care in diabetes--2011.

25 August 2017

1 reference

Pharmacological management of type 2 diabetes mellitus: rationale for rational use of insulin

21 January 2018

1 reference

Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications

21 January 2018

1 reference

Renal sodium-glucose transport: role in diabetes mellitus and potential clinical implications

21 January 2018

1 reference

Renal gluconeogenesis: its importance in human glucose homeostasis

21 January 2018

1 reference

Liver and kidney metabolism during prolonged starvation

21 January 2018

1 reference

The Contrasting Responses of Splanchnic and Renal Glucose Output to Gluconeogenic Substrates and to Hypoglucagonemia in 60-h-fasted Humans

21 January 2018

1 reference

Contributions by kidney and liver to glucose production in the postabsorptive state and after 60 h of fasting.

21 January 2018

1 reference

Glucose metabolism in renal tubular function

21 January 2018

1 reference

The human kidney low affinity Na+/glucose cotransporter SGLT2. Delineation of the major renal reabsorptive mechanism for D-glucose

21 January 2018

1 reference

Active sugar transport in health and disease

21 January 2018

1 reference

Sodium-glucose transporter-2 inhibition as an antidiabetic therapy

21 January 2018

1 reference

Abnormal renal and hepatic glucose metabolism in type 2 diabetes mellitus

21 January 2018

1 reference

Abnormal renal, hepatic, and muscle glucose metabolism following glucose ingestion in type 2 diabetes

21 January 2018

1 reference

Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes

21 January 2018

1 reference

Familial renal glucosuria and SGLT2: from a mendelian trait to a therapeutic target.

21 January 2018

1 reference

Long-term outcome of renal glucosuria type 0: the original patient and his natural history

21 January 2018

1 reference

Familial renal glucosuria: SLC5A2 mutation analysis and evidence of salt-wasting

21 January 2018

1 reference

Twenty-one additional cases of familial renal glucosuria: absence of genetic heterogeneity, high prevalence of private mutations and further evidence of volume depletion

21 January 2018

1 reference

Glucose transporters: structure, function and consequences of deficiency

21 January 2018

1 reference

21 January 2018

1 reference

Normalization of blood glucose in diabetic rats with phlorizin treatment reverses insulin-resistant glucose transport in adipose cells without restoring glucose transporter gene expression.

21 January 2018

1 reference

Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats

21 January 2018

1 reference

Glucose control by the kidney: an emerging target in diabetes

21 January 2018

1 reference

Development of the renal glucose reabsorption inhibitors: a new mechanism for the pharmacotherapy of diabetes mellitus type 2.

21 January 2018

1 reference

Is glycemic control improving in U.S. adults?

21 January 2018

1 reference

Diabetes prevalence and therapeutic target achievement in the United States, 1999 to 2006.

21 January 2018

1 reference

Projection of the year 2050 burden of diabetes in the US adult population: dynamic modeling of incidence, mortality, and prediabetes prevalence

21 January 2018

1 reference

Remogliflozin etabonate, in a novel category of selective low-affinity sodium glucose cotransporter (SGLT2) inhibitors, exhibits antidiabetic efficacy in rodent models

21 January 2018

1 reference

Sergliflozin etabonate, a selective SGLT2 inhibitor, improves glycemic control in streptozotocin-induced diabetic rats and Zucker fatty rats

21 January 2018

1 reference

Single-dose pharmacokinetics and pharmacodynamics of sergliflozin etabonate, a novel inhibitor of glucose reabsorption, in healthy volunteers and patients with type 2 diabetes mellitus

21 January 2018

1 reference

In vitro characterization and pharmacokinetics of dapagliflozin (BMS-512148), a potent sodium-glucose cotransporter type II inhibitor, in animals and humans

21 January 2018

1 reference

Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats

21 January 2018

1 reference

Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes

21 January 2018

1 reference

Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects

21 January 2018

1 reference

Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus

21 January 2018

1 reference

Effect of human renal cationic transporter inhibition on the pharmacokinetics of varenicline, a new therapy for smoking cessation: an in vitro-in vivo study

21 January 2018

1 reference

Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes

21 January 2018

1 reference

A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment

21 January 2018

1 reference

Dapagliflozin treatment in patients with different stages of type 2 diabetes mellitus: effects on glycaemic control and body weight

21 January 2018

1 reference

Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial

21 January 2018

1 reference

Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial.

21 January 2018

1 reference

Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial

21 January 2018

1 reference

Increased risk of common infections in patients with type 1 and type 2 diabetes mellitus.

21 January 2018

1 reference

Pathogenesis and management of bacterial urinary tract infections in adult patients with diabetes mellitus

21 January 2018

1 reference

Inhibition of SGLT2: a novel strategy for treatment of type 2 diabetes mellitus

21 January 2018

1 reference

Quantitative PCR tissue expression profiling of the human SGLT2 gene and related family members

21 January 2018

1 reference

The novel sodium glucose transporter 2 inhibitor dapagliflozin sustains pancreatic function and preserves islet morphology in obese, diabetic rats

21 January 2018

1 reference

Need for better diabetes treatment for improved renal outcome

21 January 2018

1 reference

The hypothalamus and ß-cell connection in the gene-targeting era.

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1586/ECP.11.54

1 reference

25 August 2017

1 reference

PubMed ID

22111852